Study of Obesity Control by Astragalus and Notoginseng Extrats

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03654391

Enrollment

Registered

2018-08-31

Start date

2016-10-31

Completion date

2017-10-31

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Astragalus and Notoginseng extrats, Body weight, BMI, Triglyceride, obese

Brief summary

The effects of the Astragalus and Notoginseng extrats on obesity control was demonstrated in a randomized double-blind, and crossover human trial.

Detailed description

Obesity refers to the body due to physiological or biochemical function of the change caused by excessive accumulation of body fat, resulting in weight gain. Hence, the aim of this study was to evaluate the effects of the Astragalus and Notoginseng extrats on obesity control by a randomized double-blind and crossover human trial. Subjects with simple obesity (body mass index (BMI) ≥ 27 or body fat ≥ 30%) ingested 5 extrats (n = 19) capsules or placebo (n = 19) perday for 12 weeks of a stage. Anthropometric measurements (body weight, body fat, blood pressure) and blood biochemical markers including fasting blood glucose (FBG), albumin, total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, creatinine (Cr), blood urea nitrogen (BUN), AST, ALT were examined every six weeks.

Interventions

DIETARY_SUPPLEMENTInnoSlim

Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.

DIETARY_SUPPLEMENTPlacebo

Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Body mass index (BMI) ≥ 27 or body fat ≥ 30%; * No history of serious diseases associated with heart, liver, kidney, endocrine systems or other organs; * No drugs consumption.

Exclusion criteria

* BMI \>35; * Alcoholic; * US-controlled diabetics; * Stoke in past one year; * High blood pressure; * Mental diseases or melancholia; * Pregency or breast-feeding a child.

Design outcomes

Primary

Measure	Time frame	Description
The changes of body weight and BMI of the subjects.	12 weeks	values change of body weight and BMI between before to after 12 weeks

Secondary

Measure	Time frame	Description
The changes of triglyceride (TG) of the subjects	12 weeks	values change of triglyceride (TG) between before to after 12 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026